Abstract
In recent years, the number of oral anticancer agents (OACA), protein kinase inhibitors (PKI or “nibs”), in particular, has sharply increased. In the near future, the rise is likely to continue. OACA are used in the treatment of both common cancer types and a wide variety of less commonly occurring cancers and hematological malignancies. Due to the spreading use of OACA in cancer treatment pharmacists (and staff) of outpatient pharmacies are becoming more closely involved in the disease’s main treatment and directly interact with predominantly older cancer patients and other caregivers. Providing pharmaceutical care for cancer outpatients requires specific knowledge of cancer (drug) therapy, pharmacogenomics, contraindications, interactions of OACA with other drugs and food, side effects, and their management and patient education .Within the framework of a multidisciplinary team effort, the pharmacist dispensing OACA must assess the suitability of its use for the patient and address eventual problems that the treatment entails, notably with respect to supportive and current medication for chronic diseases. The pharmacist is also responsible for adequate patient counseling . Adherence to OACA treatment and effects brought about by OACA and co-medication require careful monitoring of the patient and his/her use of medication. Close collaboration with other healthcare providers, both in the case of prescribing OACA and co-medication and with respect to events occurring during the course of treatment as the result of disease progression, side effects or incorrect medication use, is the most appropriate way to resolve eventual problems and adequately adjust treatment. In the present chapter, the various steps of the pharmaceutical care process, conditions for its successful completion and the role of the pharmacist in it, are lined out and the main topics that have to be addressed during this process including the detection and management of drug interactions, the reporting and management of side effects, (non-) adherence and adherence supportive care, and last but not least, patient counseling are discussed. The basic approach is that pharmacists are partners of (primary care) physicians as they collaborate on a wide variety of care activities including the optimization of treatment, medication reconciliation, patient education , and medication safety.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roskoski R. A historical overview of protein kinases and their small molecule inhibitors. Pharmacol Res. 2015;100:1–23.
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, et al. The target landscape of clinical kinase drugs. Science 2017;358:eaan4368.
Leveque D, Delpuech A, Gourieux B. New anticancer agents: role of clinical pharmacy services. Anticancer Res. 2014;34:1573–8.
Holle LM, Boehnke-Michaud L. Oncology pharmacists in health care delivery: vital members of the cancer care team. J Oncol Pract. 2014;10:e142–5.
Dalby M. Current models of support from community pharmacists for patients on oral anticancer medicines. J Oncol Pharm Pract. 2017 September 26. https://doi.org/10.1177/1078155217732399.
Timmers L, Boons CC, Verbrugghe M, van den Bemt BJ, Van Hecke A, Hugtenburg JG. Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer. 2017;17:122–33.
Boons CCLM, Timmers L, van Schoor NM, Swart EL, Hendrikse NH, Janssen JJWM, Hugtenburg JG. Patient satisfaction with information on oral anticancer agent use. Cancer Med. 2018;7:219–28.
Cassidy J, Bissett D, Spence RAJ, Payne M, Morris-Stiff G. Oxford Handbook of Oncology (4th edition). Oxford: Oxford University Press; 2015.
Ribed A, Escudero-Vilaplana V, Romero-Jimenez RM, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo-Saez M. Guiding pharmacist clinical interviews: a safety tool to support the education of patient treated with oral antineoplastic agents. Expert Opin Drug Safety. 2016;15:427–35.
Broadfield L, Shaheen P, Rogez M, et al. Guidelines for outpatient cancer care by community pharmacists. CPJ. 2017;150:24–31.
Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249–57.
Bertholee D, Maring JG, Van Kuilenburg ABP. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2017;56:317–37.
Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Leveque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two—targeted therapies. Eur J Cancer. 2014;50:2020–36.
Boons CLM, Swart EL, Timmers L, Van de Ven PM, Jansen JJWN, Hugtenburg JG. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia. BMC Cancer. 2014;14:247–52.
Van Leeuwen RWF, Van Gelder T, Matthijsen RH, Janssen FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:e315–26.
Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Practice. 2014;10:e255–68.
Timmers L1, Boons CC, Kropff F, van de Ven PM, Swart EL, Smit EF, et al. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol 2014;53:259–267.
Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21:354–76.
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.
Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Hugtenburg, J.G., Timmers, L., Beckeringh, J.J. (2019). Pharmaceutical Care for Cancer Outpatients. In: Alves da Costa, F., van Mil, J., Alvarez-Risco, A. (eds) The Pharmacist Guide to Implementing Pharmaceutical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-92576-9_32
Download citation
DOI: https://doi.org/10.1007/978-3-319-92576-9_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92575-2
Online ISBN: 978-3-319-92576-9
eBook Packages: MedicineMedicine (R0)